OBJECTIVES: Conduct an economic evaluation comparing treatment costs between 5% and 10% Intravenous Immunoglobulin (IVIG) preparations. METHODS: A cost-minimization analysis (CMA) was performed to compare treatment costs between five 5% (including one lyophilized product) and one 10% IVIG preparations, as there are no differences in outcomes achieved between different IVIG preparations. The CMA was done using a societal perspective and cost included both healthcare costs as well as caregiver costs.  More specifically, the following costs were considered in the model: drug costs, facility costs, pharmacy and nursing costs and productivity costs.  Other data included in the model were obtained from the products’ prescribing information. One adult patient (65kg) and one pediatric patient (25kg) receiving a dose of 0.4g/kg were modeled. RESULTS: Even though equal cost per gram was assumed across all the IVIG products considered in the model, total drug cost was higher for one of the 5% product because of the limited choice in vial sizes for this particular product. Only the lyophilized product incurred pharmacy costs for reconstitution ($15.0).  Infusion time was shortened by 51 minutes with the 10% product (2.0h compared to the 5% products (2.9h), saving approximately $21.4 per infusion.  For the adult patient, nursing costs were higher for the 5% products as more vials were required during the infusion (4 to 5 vials for 5% vs. 3 for 10%).  On average, the use of a 10% preparation saved $65.2 per dose for the adult patient and $32.7 per dose for the pediatric patient.  Assuming a dosing frequency of 3 weeks, yearly savings could range between $522.2 and $3.072.2 in adults and $486.8 and $831.6 in children.  CONCLUSIONS: The availability of a 10% IVIG preparation could generate substantial savings compared to 5% preparations.